Advertisement

Advertisement
Immunotherapy

How Turning ‘Cold’ Tumors Into ‘Hot’ Ones May Improve Response to Immunotherapy

The proliferation of immunotherapeutics in the treatment of cancer over the past decade has revolutionized the way many cancers are treated, especially lung cancer and melanoma...

Myelodysplastic Syndromes

Novel Treatments of Myelodysplastic Syndromes

As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology Annual Meeting & Exposition, here is an update on seven different studies on new therapeutics...

Lung Cancer

Encourage Lung Cancer Screening to Prevent Early Deaths

Discussions of benefits and harms from screening of high-risk populations for lung cancer have missed the point. The National Lung Screening Trial (NLST) showed an early and statistically significant...


Advertisement
Lung Cancer

Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC

In a global phase II study reported in The Lancet OncologyBenjamin J. Solomon, MBBS, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that lorlatinib...

Lymphoma
Survivorship

Living My Best Life

But then my life took a drastic turn. Suddenly, a lump popped up on the left side of my neck, which I initially attributed to my body’s way of fighting off an infection...

 

Advertisement




More Top Stories

Issues in Oncology

Norman E. Sharpless, MD: Director of the National Cancer Institute: Articulating a Vision

Issues in Oncology

Clinical Cancer Advances 2019: ASCO Names Advance of the Year, Debuts Research Priorities for the Cancer Community

In the release of its annual report on progress against cancer, Clinical Cancer Advances 2019, ASCO recognized progress in treating rare cancers as the Advance of the Year. The report catalogs a year’s worth of remarkable research advancements, reinforces the need for continued federal research...

Advertisement

New Approach to Predicting Response to Pertuzumab and Trastuzumab in Breast Cancer

In the phase II TBCRC026 study reported in the Journal of Clinical Oncology, Connolly et al found that early changes in tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were...

Breast Cancer
Genomics/Genetics

Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care

NCCN Guidelines Exceed 10 Million Downloads in 2018

THE NATIONAL Comprehensive Cancer Network® (NCCN®) announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) were downloaded more than 10 million times in 2018, marking a 26% increase over downloads in 2017. The NCCN Guidelines provide up-to-date recommendations for...

Amy Abernethy, MD, PhD, Named Principal Deputy Commissioner of Food and Drugs

ON DECEMBER 17, 2018, the U.S. Food and Drug Administration (FDA) announced that Amy Abernethy, MD, PhD, will replace Rachel Sherman, MD, MPH, as Principal Deputy Commissioner of Food and Drugs. Dr. Abernethy most recently served as Chief Medical Officer, Chief Scientific Officer, and Senior...

Involvement of Primary Care Providers in Cancer Treatment Decisions

The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors, but research has shown patients are also discussing initial cancer treatment options with their primary care doctors. Now, a new study by Wallner et al in Cancer has...

Colorectal Cancer

Pieter Tanis, MD, PhD, on Colon Cancer: Results From the COLOPEC Trial on Adjuvant HIPEC

Head and Neck Cancer

KEYNOTE-181: Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Esophageal Cancer

In the global phase III KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced esophageal cancer did not improve overall survival in the whole population, vs chemotherapy, but did improve survival for patients with strong expression of programmed cell death ligand 1 (PD-L1),...

Advertisement

System-Based Intervention to Reduce Racial Disparities in Early-Stage Lung Cancer Treatment

Results from a study published by Cykert et al in Cancer Medicine showed that a pragmatic system-based intervention within cancer treatment centers may eliminate existing disparities in treatment and outcomes for black patients with early-stage lung cancer. “These results show ...